Akkermansia Research Guide

Full name: Akkermansia muciniphila (Pasteurized)

A keystone gut bacterium that resides in the mucus layer and is inversely correlated with obesity, diabetes, and metabolic syndrome. Pasteurized form retains metabolic benefits through its membrane protein Amuc_1100.

How Akkermansia Works

Amuc_1100 outer membrane protein activates TLR2 signaling, strengthening gut barrier and improving metabolic endotoxemia. Stimulates mucin production by goblet cells. Enhances GLP-1 secretion and improves insulin signaling.

Dosing Protocol

• Typical dose: 10 billion CFU (pasteurized) or 100mg membrane extract
• Frequency: Daily
• Duration: Ongoing (8-12 weeks minimum for metabolic effects)
• Route: Oral capsule

Reported Benefits

• Improved metabolic markers
• Reduced insulin resistance
• Gut barrier strengthening
• Weight management support
• Reduced systemic inflammation
• Enhanced GLP-1 secretion

Potential Side Effects

• Mild GI adjustment period
• Temporary bloating
• Generally very well-tolerated

Research Citations

1. Pasteurized Akkermansia and metabolic syndrome (2022) - Improved insulin sensitivity by 30%, reduced LPS endotoxemia, and decreased body weight by 2.3kg over 12 weeks vs placebo.
2. Akkermansia and GLP-1 axis (2021) - Amuc_1100 protein increased GLP-1 secretion by 2-fold in human enteroendocrine cell models, independent of live bacterial colonization.

Related Gut Health Compounds

• Larazotide - Full Profile
• Colostrum - Full Profile
• BPC-157 Oral (Gut) - Full Profile
• Butyrate - Full Profile
• Ovagen - Full Profile

View full Akkermansia profile with 3D molecule viewer →